Immediate and long-term impact of the COVID-19 pandemic on cardiovascular clinical trials: considerations for study conduct and endpoint determination
EuroIntervention
.
2020 Nov 20;16(10):787-793.
doi: 10.4244/EIJV16I10A147.
Authors
Alexandra Lansky
1
,
Tayyab Shah
,
William Wijns
,
Giulio G Stefanini
,
Andrew Farb
,
Aaron Kaplan
,
Bo Xu
,
Cody Pietras
,
Eric Velazquez
,
Patrick W Serruys
,
Felix Mahfoud
,
Andreas Baumbach
Affiliation
1
Yale University School of Medicine, New Haven, CT, USA.
PMID:
33215993
DOI:
10.4244/EIJV16I10A147
No abstract available
MeSH terms
COVID-19*
Cardiovascular Diseases* / therapy
Clinical Trials as Topic
Endpoint Determination*
Humans
Pandemics
SARS-CoV-2